Market Summary
USD9.06+0.07
Market Closed0.78%
TBPH Stock Price
TBPH RSI Chart
TBPH Valuation
TBPH Price/Sales (Trailing)
TBPH Profitability
TBPH Fundamentals
TBPH Revenue
TBPH Earnings
Price Action
52 Week Range
8.7612.03
(Low)(High)
Last 7 days
-8.2%
Last 30 days
-4.6%
Last 90 days
-16.2%
Trailing 12 Months
-11.3%
TBPH Financial Health
TBPH Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TBPH
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-14 | GRAHAM RICHARD A | sold | -24,547 | 9.89 | -2,482 | svp, research & development |
2023-08-22 | Farnum Rhonda | sold | -17,112 | 9.47 | -1,807 | svp, comm & medical affairs |
2023-08-20 | Winningham Rick E | sold (taxes) | -153,299 | 9.7 | -15,804 | chief executive officer |
2023-08-20 | Sawaf Aziz | sold (taxes) | -69,005 | 9.7 | -7,114 | svp & chief financial officer |
2023-08-20 | GRAHAM RICHARD A | sold (taxes) | -101,472 | 9.7 | -10,461 | svp, research & development |
2023-08-20 | Grimaud Brett A. | sold (taxes) | -86,446 | 9.7 | -8,912 | svp, gen counsel and secretary |
2023-08-20 | Farnum Rhonda | sold (taxes) | -101,462 | 9.7 | -10,460 | svp, comm & medical affairs |
2023-08-11 | GRAHAM RICHARD A | sold | -23,196 | 9.99 | -2,322 | svp, research & development |
2023-07-14 | GRAHAM RICHARD A | sold | -22,848 | 9.84 | -2,322 | svp, research & development |
2023-06-14 | GRAHAM RICHARD A | sold | -24,822 | 10.69 | -2,322 | svp, research & development |
Which funds bought or sold TBPH recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | unchanged | - | -69.00 | 1,428 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.32 | -72,150 | 672,854 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 1.82 | -48,645 | 1,628,360 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 1.24 | -125,033 | 3,525,200 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 81.07 | 106,366 | 252,623 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | -38,868 | 804,557 | -% |
2023-08-14 | Bleakley Financial Group, LLC | new | - | 245,295 | 245,295 | 0.01% |
2023-08-14 | CANTOR FITZGERALD, L. P. | unchanged | - | -10,000 | 207,000 | -% |
2023-08-14 | Graham Capital Management, L.P. | reduced | -18.23 | -42,789 | 151,751 | -% |
2023-08-14 | PDT Partners, LLC | reduced | -0.25 | -43,282 | 850,335 | 0.12% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Theravance Biopharma
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Aug 14, 2023 | weiss asset management lp | 14.% | 7,457,060 | SC 13D/A | |
| Jul 10, 2023 | baupost group llc/ma | 12.84% | 7,419,226 | SC 13G/A | |
| Apr 12, 2023 | weiss asset management lp | 11.% | 7,457,060 | SC 13D | |
| Feb 14, 2023 | madison avenue partners, lp | 10.4% | 7,012,226 | SC 13G/A | |
| Feb 14, 2023 | orbimed advisors llc | 0% | 0 | SC 13G/A | |
| Feb 13, 2023 | baupost group llc/ma | 16.95% | 11,419,226 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.25% | 5,558,839 | SC 13G/A | |
| Jan 30, 2023 | barclays plc | 5.00% | 3,371,298 | SC 13G | |
| Sep 20, 2022 | gsk plc | 0.0% | 0 | SC 13D/A | |
| Jun 16, 2022 | weiss asset management lp | 8.09% | 6,157,360 | SC 13G |
Recent SEC filings of Theravance Biopharma
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 12, 2023 | 8-K | Current Report | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 4 | Insider Trading | |
| Aug 15, 2023 | 4 | Insider Trading |
TBPH Fair Value
Loading...
Peers (Alternatives to Theravance Biopharma)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
PRVB | 2.2B | 12.9M | 4.30% | 396.62% | -19.28 | 169.83 | 824.37% | 0.76% |
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
PCRX | 1.6B | 669.2M | -8.68% | -37.33% | -350.4 | 2.39 | 8.94% | -111.64% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
TBPH | 486.5M | 51.3M | -4.63% | -11.35% | 0.56 | 9.49 | -2.14% | 955.88% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
NGM | 100.9M | 29.7M | -47.86% | -91.50% | -0.59 | 3.39 | -56.77% | -25.62% |
Theravance Biopharma News
Returns for TBPH
Cumulative Returns on TBPH
-17.7%
7-Year Cumulative Returns
-20.8%
5-Year Cumulative Returns
-20.2%
3-Year Cumulative Returns
Risks for TBPH
What is the probability of a big loss on TBPH?
87.3%
Probability that Theravance Biopharma stock will be more than 20% underwater in next one year
81.9%
Probability that Theravance Biopharma stock will be more than 30% underwater in next one year.
53.1%
Probability that Theravance Biopharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TBPH drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Theravance Biopharma was unfortunately bought at previous high price.
Drawdowns
Financials for Theravance Biopharma
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 5.6% | 51,266,000 | 48,567,000 | 51,346,000 | 51,643,000 | 52,386,000 | 54,250,000 | 55,311,000 | 59,095,000 | 64,158,000 | 66,252,000 | 71,857,000 | 82,626,000 | 76,796,000 | 87,938,000 | 73,414,000 | 59,652,000 | 60,063,000 | 57,389,000 | 60,370,000 | 49,148,000 | 40,585,000 |
| Operating Expenses | -3.5% | 118,877,000 | 123,156,000 | 138,246,000 | 177,278,000 | 222,492,000 | 265,365,000 | 313,095,000 | 337,202,000 | 365,265,000 | 375,425,000 | 369,614,000 | 374,465,000 | 357,221,000 | 338,663,000 | 325,329,000 | 303,616,000 | 301,276,000 | 304,830,000 | 299,121,000 | 304,454,000 | 290,438,000 |
| S&GA Expenses | 4.5% | 70,706,000 | 67,650,000 | 67,073,000 | 71,857,000 | 76,879,000 | 86,588,000 | 99,296,000 | 107,705,000 | 113,907,000 | 112,756,000 | 108,531,000 | 111,652,000 | 109,773,000 | 107,220,000 | 106,081,000 | 98,492,000 | 94,760,000 | 97,540,000 | 97,058,000 | 101,124,000 | 100,178,000 |
| R&D Expenses | -10.2% | 48,565,000 | 54,064,000 | 63,392,000 | 79,270,000 | 113,142,000 | 149,311,000 | 193,657,000 | 227,596,000 | 251,228,000 | 262,539,000 | 260,953,000 | 262,813,000 | 247,448,000 | 231,443,000 | 219,248,000 | 204,492,000 | 205,179,000 | 207,401,000 | 201,348,000 | 200,131,000 | 186,781,000 |
| EBITDA | 100.0% | - | -46,432,000 | -86,446,000 | 23,601,000 | -6,096,000 | -98,876,000 | -152,688,000 | -187,718,000 | -226,122,000 | -233,091,000 | -238,477,000 | -240,446,000 | -234,384,000 | -214,663,000 | -206,340,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.96 | -1.68 | 0.46 | -0.12 | -1.82 | -2.76 | -3.18 | -3.52 | -3.52 | -3.32 | -2.91 | -3.05 | -2.44 | -2.81 | - | - | - | - | - | - |
| Interest Expenses | -32.8% | 3,213,000 | 4,782,000 | 6,369,000 | 7,956,000 | 8,547,000 | 18,022,000 | 8,547,000 | 1,263,000 | 10,700,000 | 10,479,000 | 8,547,000 | 40,940,000 | 37,435,000 | 33,945,000 | 31,862,000 | 27,898,000 | 21,967,000 | 16,203,000 | 10,482,000 | 8,548,000 | 8,547,000 |
| Earnings Before Taxes | 11.4% | -66,952,000 | -75,563,000 | -92,815,000 | -136,522,000 | -176,416,000 | -206,243,000 | -265,222,000 | -272,033,000 | -289,666,000 | -299,889,000 | -303,343,000 | -284,861,000 | -275,294,000 | -252,083,000 | -241,677,000 | -229,562,000 | -225,671,000 | -233,642,000 | -226,085,000 | -252,576,000 | -258,493,000 |
| EBT Margin | 100.0% | - | -1.26 | -1.81 | -0.81 | -1.56 | -2.68 | -3.61 | -3.97 | -4.25 | -4.27 | -3.99 | -3.45 | -3.58 | -2.87 | -3.29 | - | - | - | - | - | - |
| Net Income | -0.9% | 868,536,000 | 875,990,000 | 872,132,000 | 850,460,000 | -101,479,000 | -145,693,000 | -199,426,000 | -225,826,000 | -264,161,000 | -274,643,000 | -278,017,000 | -285,189,000 | -269,977,000 | -246,928,000 | -236,455,000 | -221,035,000 | -222,037,000 | -223,017,000 | -215,524,000 | -252,260,000 | -259,704,000 |
| Net Income Margin | -100.0% | - | 18.04 | 16.99 | 16.47 | -1.94 | -2.69 | -3.61 | -3.82 | -4.12 | -4.15 | -3.87 | -3.45 | -3.52 | -2.81 | -3.22 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -172,143,000 | -186,991,000 | -105,370,000 | -128,679,000 | -164,062,000 | -207,858,000 | -230,349,000 | -261,934,000 | -267,302,000 | -252,538,000 | -251,965,000 | -219,556,000 | -214,240,000 | -240,332,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -17.1% | 447 | 539 | 607 | 763 | 361 | 355 | 375 | 403 | 429 | 375 | 469 | 512 | 564 | 605 | 409 | 445 | 492 | 531 | 560 | 371 | 421 |
| Current Assets | -26.5% | 192 | 261 | 353 | 512 | 155 | 205 | 250 | 297 | 333 | 293 | 393 | 451 | 498 | 534 | 338 | 356 | 426 | 467 | 533 | 333 | 387 |
| Cash Equivalents | -43.7% | 106 | 188 | 298 | 419 | 87.00 | 94.00 | 91.00 | 121 | 205 | 114 | 81.00 | 93.00 | 105 | 333 | 59.00 | 102 | 178 | 223 | 379 | 101 | 104 |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00 | 18.00 |
| Net PPE | -21.1% | 10.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 | 16.00 | 17.00 | 17.00 | 16.00 | 15.00 | 14.00 | 14.00 | 13.00 | 12.00 | 13.00 | 13.00 | 13.00 | 12.00 | 11.00 |
| Current Liabilities | -6.3% | 25.00 | 26.00 | 29.00 | 142 | 33.00 | 44.00 | 59.00 | 66.00 | 67.00 | 86.00 | 124 | 104 | 107 | 98.00 | 112 | 109 | 110 | 114 | 99.00 | 102 | 93.00 |
| Shareholder's Equity | -24.4% | 280 | 371 | 442 | 481 | -349 | -351 | -338 | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.00 |
| Retained Earnings | -1.8% | -891 | -876 | -853 | -843 | -1,760 | -1,751 | -1,726 | -1,694 | -1,658 | -1,606 | -1,526 | -1,468 | -1,394 | -1,331 | -1,248 | -1,182 | -1,124 | -1,084 | -1,012 | -961 | -902 |
| Additional Paid-In Capital | -6.0% | 1,172 | 1,247 | 1,296 | 1,324 | 1,410 | 1,401 | 1,387 | 1,370 | 1,358 | 1,233 | 1,223 | 1,207 | 1,192 | 1,173 | 1,025 | 1,000 | 987 | 972 | 961 | 949 | 937 |
| Shares Outstanding | -11.3% | 54.00 | 61.00 | 65.00 | 67.00 | 76.00 | 75.00 | 74.00 | 74.00 | 66.00 | 64.00 | 64.00 | 63.00 | 61.00 | 59.00 | 57.00 | 56.00 | 55.00 | 55.00 | 54.00 | 54.00 | 54.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 1.3% | -169 | -172 | -186 | -105 | -128 | -164 | -207 | -230 | -261 | -265 | -250 | -249 | -217 | -212 | -238 | -226 | -230 | -243 | -112 | -104 | -118 |
| Share Based Compensation | -10.7% | 29.00 | 32.00 | 40.00 | 50.00 | 56.00 | 61.00 | 62.00 | 61.00 | 62.00 | 64.00 | 63.00 | 71.00 | 69.00 | 64.00 | 60.00 | 48.00 | 47.00 | 50.00 | 51.00 | 57.00 | 56.00 |
| Cashflow From Investing | 0.3% | 1,083 | 1,079 | 1,154 | 1,126 | 14.00 | 43.00 | 124 | 166 | 268 | 56.00 | 11.00 | -27.59 | -117 | 58.00 | -83.05 | 2.00 | 73.00 | 116 | 177 | 119 | 87.00 |
| Cashflow From Financing | -9.9% | -894 | -813 | -758 | -723 | -3.44 | 102 | 92.00 | 92.00 | 94.00 | -9.63 | 263 | 261 | 262 | 264 | 1.00 | 232 | 232 | 225 | 225 | -3.77 | -4.24 |
| Buy Backs | 7.8% | 265 | 246 | 129 | 376 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
TBPH Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |||
| Revenue: | ||||||
| Total revenue | $ 13,749 | $ 11,050 | $ 24,166 | $ 24,246 | ||
| Expenses: | ||||||
| Research and development (1) | [1] | 9,425 | 14,924 | 23,997 | 38,177 | |
| Selling, general and administrative (1) | [1] | 19,278 | 16,222 | 38,461 | 34,064 | |
| Restructuring and related expenses (1) | [1] | 1,169 | 3,005 | 2,743 | 12,329 | |
| Total expenses | 29,872 | 34,151 | 65,201 | 84,570 | ||
| Loss from operations | (16,123) | (23,101) | (41,035) | (60,324) | ||
| Interest expense | (568) | (2,137) | (1,118) | (4,274) | ||
| Interest income and other income (expense), net | 2,504 | 2,440 | 5,483 | 2,065 | ||
| Loss from continuing operations before income taxes | (14,187) | (22,798) | (36,670) | (62,533) | ||
| Provision for income tax (expense) benefit | (1,458) | 5 | (1,063) | (519) | ||
| Net loss from continuing operations | (15,645) | (22,793) | (37,733) | (63,052) | ||
| Income from discontinued operations before income taxes | 14,602 | 28,915 | ||||
| Provision for income tax expense | ||||||
| Net income from discontinued operations | 14,602 | 28,915 | ||||
| Net loss | (15,645) | (8,191) | (37,733) | (34,137) | ||
| Net unrealized loss on available-for-sale investments | (337) | (17) | (271) | (45) | ||
| Total comprehensive loss | $ (15,982) | $ (8,208) | $ (38,004) | $ (34,182) | ||
| Net income (loss) per share: | ||||||
| Continuing operations - basic | $ (0.28) | $ (0.30) | $ (0.63) | $ (0.83) | ||
| Continuing operations - diluted | (0.28) | (0.30) | (0.63) | (0.83) | ||
| Discontinued operations - basic | 0.19 | 0.38 | ||||
| Discontinued operations - diluted | 0.19 | 0.38 | ||||
| Net loss - basic | (0.28) | (0.11) | (0.63) | (0.45) | ||
| Net loss - diluted | $ (0.28) | $ (0.11) | $ (0.63) | $ (0.45) | ||
| Shares used to compute net income (loss) per share - basic | 56,682 | 76,270 | 59,791 | 75,761 | ||
| Shares used to compute net income (loss) per share - diluted | 56,682 | 76,270 | 59,791 | 75,761 | ||
| Total share-based compensation expense | $ 6,264 | $ 9,709 | $ 13,285 | $ 24,254 | ||
| Research and development | ||||||
| Expenses: | ||||||
| Restructuring and related expenses (1) | 1,200 | 1,000 | 2,700 | 5,700 | ||
| Net income (loss) per share: | ||||||
| Total share-based compensation expense | 1,855 | 2,909 | 4,296 | 7,439 | ||
| Selling, general and administrative | ||||||
| Expenses: | ||||||
| Restructuring and related expenses (1) | 2,000 | 6,600 | ||||
| Net income (loss) per share: | ||||||
| Total share-based compensation expense | 4,409 | 5,030 | 8,632 | 10,528 | ||
| Restructuring and related expenses | ||||||
| Net income (loss) per share: | ||||||
| Total share-based compensation expense | 1,770 | 357 | 6,287 | |||
| Viatris collaboration agreement | ||||||
| Revenue: | ||||||
| Total revenue | 13,743 | 10,878 | 24,154 | 21,565 | ||
| Collaboration revenue | ||||||
| Revenue: | ||||||
| Total revenue | $ 6 | $ 172 | $ 12 | 181 | ||
| Licensing revenue | ||||||
| Revenue: | ||||||
| Total revenue | $ 2,500 | |||||
| ||||||
TBPH Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 105,596 | $ 298,172 |
| Short-term marketable securities | 61,855 | 29,312 |
| Receivables from collaborative arrangements | 15,796 | 16,785 |
| Prepaid clinical and development services | 979 | 1,513 |
| Other prepaid and current assets | 7,777 | 7,682 |
| Total current assets | 192,003 | 353,464 |
| Property and equipment, net | 9,553 | 11,875 |
| Operating lease assets | 38,453 | 40,126 |
| Future contingent milestone and royalty assets | 194,200 | 194,200 |
| Restricted cash | 836 | 836 |
| Other assets | 11,585 | 6,899 |
| Total assets | 446,630 | 607,400 |
| Current liabilities: | ||
| Accounts payable | 1,569 | 1,554 |
| Accrued personnel-related expenses | 5,371 | 10,314 |
| Accrued clinical and development expenses | 4,006 | 4,932 |
| Accrued general and administrative expenses | 2,874 | 4,020 |
| Operating lease liabilities | 9,160 | 6,753 |
| Deferred revenue | 24 | 24 |
| Other accrued liabilities | 1,542 | 1,118 |
| Total current liabilities | 24,546 | 28,715 |
| Long-term operating lease liabilities | 42,521 | 45,407 |
| Future royalty payment contingency | 26,556 | 25,438 |
| Long-term deferred revenue | 181 | 192 |
| Unrecognized tax benefits | 64,987 | 64,191 |
| Other long-term liabilities | 7,678 | 1,657 |
| Commitments and contingencies | ||
| Shareholders' Equity | ||
| Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding | ||
| Ordinary shares, $0.00001 par value: 200,000 shares authorized; 53,694 and 65,227 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 1 | 1 |
| Additional paid-in capital | 1,172,090 | 1,295,725 |
| Accumulated other comprehensive loss | (286) | (15) |
| Accumulated deficit | (891,644) | (853,911) |
| Total shareholders' equity | 280,161 | 441,800 |
| Total liabilities and shareholders' equity | $ 446,630 | $ 607,400 |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.